Singapore, Sept. 23 -- Simcere Pharmaceuticals Group has launchedQUVIVIQ(R)(daridorexant)in China.In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for QUVIVIQ in Greater China (Mainland China, Hong Kong, and Macau). Under the agreement, Simcere has the exclusive right to develop and commercialise QUVIVIQ in Greater China; Idorsia has to date received $80 million in milestone payments from Simcere.

QUVIVIQ, Idorsia's dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterised by difficulty falling asleep and/or maintaining sleep. Notably, QUVIVIQ has been approved without psychotropic drug control labeling, underscoring its differentiated clinical profile.

Insomn...